Ozempic Likely Target for 2027 Medicare Price Negotiations

Analysts predict Novo Nordisk's diabetes drug will be included in the next round of Medicare price cuts under the Inflation Reduction Act.

The Biden administration's recent Medicare price negotiations aim to reduce healthcare costs significantly.
Ozempic, a popular diabetes and weight loss drug, could be included in the 2027 list of negotiated drugs.
Other potential candidates for 2027 include Pfizer's Ibrance and Xtandi, and GSK's Trelegy Ellipta.
Pharmaceutical companies express concerns over the impact on innovation but remain cautiously optimistic about managing financial effects.
The Congressional Budget Office estimates the government will save $9.4 billion from these negotiations by 2027.